Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.

Name: Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia. | neurotech
Published: 2017-06-17T20:13:00+00:00

Home » Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.

View PDF Version

Main Phone Number

Headquarters

900 Highland Corporate Drive,
Suite 101

Cumberland, RI 02864

Commercial Office

75 Second Ave, Suite 700

Needham, MA 02494

⇧